Turn Therapeutics (NASDAQ:TTRX) Upgraded to Hold at WBB Securities

Turn Therapeutics (NASDAQ:TTRX) was upgraded by investment analysts at WBB Securities from a “sell” rating to a “hold” rating in a research note issued on Friday, Benzinga reports. The brokerage presently has a $10.00 target price on the stock. WBB Securities‘s target price points to a potential downside of 1.77% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Zacks Research raised Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded Turn Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 18th. Finally, Weiss Ratings lowered Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Turn Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Turn Therapeutics Price Performance

TTRX stock opened at $10.18 on Friday. The business has a 50 day moving average price of $11.63 and a 200 day moving average price of $8.13. The stock has a market cap of $310.80 million and a price-to-earnings ratio of -35.10. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $16.45. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Equities research analysts anticipate that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Turn Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. SteelPeak Wealth LLC grew its holdings in shares of Turn Therapeutics by 0.7% in the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after acquiring an additional 1,819 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in Turn Therapeutics during the third quarter worth $40,000. Jefferies Financial Group Inc. purchased a new stake in Turn Therapeutics during the second quarter worth $119,000. Bank of America Corp DE purchased a new stake in Turn Therapeutics during the second quarter worth $103,000. Finally, Ieq Capital LLC acquired a new stake in Turn Therapeutics in the second quarter valued at $1,660,000.

About Turn Therapeutics

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.